. The Company’s pipeline consists of 4 clinical-stage therapies. Its most Innovative drug applicant is ROS1 inhibitor taletrectinib for dealing with lung cancer. Nuvation is completing two phase two pivotal research on taletrectinib. This biography of a living person requirements additional citations for verification. Make sure you support by https://financefeeds.com/huma-surpasses-4-billion-in-transactions-just-two-weeks-after-launching-2-0-on-solana/